跳至主要内容

Non-clinical Research for Cellular Immunotherapies



Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

  • Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers.  With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare.
    Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK.  Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.
Introduction to the Test Product
  • Category：
    CAR-T CellTCR-T CellCAR-NK CellDNT CellTIL Cell
  • The complexity of Immune Cells:
    Proliferation in vivoIndividualization and heterogeneityLimited batches and productionComplicated preparation processRaw materials with huge variationsComplex biological efficacy and safety evaluation
Pharmacology and Pharmacodynamics of Cell & Gene Therapy Drugs
  • Safety Pharmacology
    Potential undesired effects of the study drug on physiological function at doses within or above the therapeutic rangeGenerally include effects on the central nervous system, cardiovascular system, and respiratory systemResearch on other organ systems may need to be supplemented depending on product characteristics
  • In vitro Pharmacodynamic Studies
    Efficacy testing of cell therapy (such as CAR-T):Tumor killing rate or proliferation inhibition rateIFN-γ expression levelPhenotype changes of CAR-T cells
    Preparation and Evaluation of CAR-T
    Preparation and Evaluation of CAR-T.webp
    Plasmid Vector Construction
    The PD-1 shRNA was integrated into the CAR plasmid, and then transduced into T cells by a lentiviral vector to obtain CAR-T cells with PD-1 silencing function.  The results showed that effective silencing of PD-1 significantly suppressed the immunosuppressive effect of the tumor microenvironment and prolonged the activation time of CAR-T cells, resulting in a longer tumor killing effect.  PD-1-silenced CAR-T cells significantly prolong the survival of mice with subcutaneous prostate and leukemia xenografts.  This demonstrated that PD-1 silencing technology is a suitable solution to promote the therapeutic effect of CAR-T cells on subcutaneous prostate and leukemia xenografts[1].  The plasmid sequencing work in this experiment was completed by Medicilon.
    Plasmid Vector Construction.webp
    CAR-T Cell Killing Assay
    CAR-T Cell Killing Assay.webp
    CAR-T cell killing experiments show that CAR-T cell-dependent killing is increased compared with Mock-T cells
  • In vivo Pharmacodynamic Studies
    Cell Therapy Test Substances
    Can be prepared from blood donated by healthy volunteersSome proof-of-concept studies could be done with alternative products of animal originThe similarities and differences between non-clinical test substances and clinical samples should be explained in the new drug application
    Gene Therapy Test Substance
    Consider factors such as production process, key quality characteristics (such as titer), preparations for clinical useIf there is species specificity, the activity of the test substance in non-clinical research should be evaluatedIf the vector uses an expression tag, the impact of the tag on the supportability of non-clinical trials should be analyzed
    Detection Methods and Evaluation Indicators
    Bioluminescent Imaging (BLI)Flow Cytometry: Detecting the number of tumor cells in animalsFlow Cytometry, ELISA, MSD: Changes in tumor-related cytokinesRelated Parameters: Tumor volume, tumor weight, tumor cell colonization site in animals and median survival period of animals
    Model Resources：
    Homologous Mouse ModelTransgenic Mouse ModelTransplanted Tumor Mouse Model

    A-target.png                B-target.png

    AB-target.jpg

    The picture shows the pharmacodynamic study of dual-target CAR-T cells in K 562 subcutaneously transplanted tumor mouse model
    Humanized Mouse Model of Immune System Reconstruction
    Humanized-Mouse-Model-of-Immune-System-Reconstruction.png
    pharmacodynamic study of the mouse pharmacodynamic model of hPBMC immune system.png
    △The picture shows the pharmacodynamic study of the mouse pharmacodynamic model of hPBMC immune system reconstruction induced by Raji-luc fluorescein-labeled lymphoma cells
    Bispecific CAR-T Efficacy Research: CD19/BCMA
    Bispecific-CAR-T-study.webp
    CAR-T cell killing experiments show that CAR-T cell-dependent killing is increased compared with Mock-T cells
Pharmacokinetic Study of Cell & Gene Therapy Drugs
  • Points to Consider for Pharmacokinetic Study:
    The parmacokinetc research studies sample in vivo behaviors, such as  distribution, proliferation and survival time. We also track transgenic product expressed and secreted outside the immune cells, if any, to provide its local and/or systemic exposure characteristics.
    Exposure: Gene therapy products should be analyzed and evaluated according to the specific characteristics of the product considering the actual exposure in non-clinical researchBiodistribution: Biodistribution of gene therapy products refers to the distribution, persistence and clearance of gene therapy products in target and non-target tissues in vivoShedding: Shedding assays should include testing for infectivity of excreted components
  • Pharmacokinetic (Biodistribution) Detection Technology：
    Imaging TechnologyFlow CytometryImmunohistochemical TechniqueQuantitative PCR TechnologyddPCRELISPot
    Detection of Distribution of Lung Cell Therapy
    Detection-of-Distribution-of-Lung-Cell-Therapy.webp
    The detection results obtained by qPCR and flow cytometry are consistent
    BD-LSRFortessa™-20-Channels.png
Nonclinical Safety Evaluation of Cell & Gene Therapy Drugs
  • In toxicology research, a comprehensive safety analysis and evaluation of gene therapy products should be conducted, and the safety of the expression products of introduced genes should also be evaluated if necessary.  Gene therapy products should be effectively introduced/exposed in relevant animal species.
    The non-clinical safety risks of cell therapy (such as CAR-T cells) mainly include:
    Cytokine release syndrome (CRS)Graft-versus-host disease (GVHD)Reversible neurotoxicityReduction of B cellsOn-target/off-tumorTumorigenicity/tumorigenicity
    Model Resources:
    Homologous Mouse ModelTransgenic Mouse ModelTransplanted Tumor Mouse ModelNon-Tumor-Bearing Immunodeficiency MiceHIS Mouse ModelVarious methods of administration such as intravenous injection, intratumoral injection, and joint cavity injection are available.
    Evaluation Content：
    Single Dose Toxicity TestRepeated Dose Toxicity TestImmunogenicity / ImmunotoxicityIn vitro Soft Agar Clone Growth TestIn vivo Tumorigenicity / TumorigenicityFormulation SafetyOther: Express Product Safety
    Reference：

    [1] Jing-E Zhou, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文